CD44 and cancer: These studies show the potential of drugs conjugated with HA as a new class of bioconjugated and tumor-targeted chemotherapeutic drugs for cancer treatment due to their innovative carrier-mediated drug delivery systems characterized by CD44-mediated endocytosis of HA and intracellular drug release with great potential.